Robert Driscoll
Stock Analyst at Wedbush
(0)
# 4019
Out of 5,218 analysts
193
Total ratings
33.58%
Success rate
-3.40%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Revolution Medicines | Maintains: Outperform | 70 67 | 44.99 | 48.92% | 3 | Dec 6, 2024 | |
Tyra Biosciences | Reiterates: Outperform | 28 28 | 14.96 | 87.17% | 8 | Oct 25, 2024 | |
Black Diamond Therap... | Reiterates: Outperform | 16 16 | 2.54 | 529.92% | 10 | Oct 8, 2024 | |
Arcus Biosciences | Reiterates: Outperform | 30 30 | 16.11 | 86.22% | 7 | Oct 3, 2024 | |
IGM Biosciences | Maintains: Outperform | 25 22 | 7.52 | 192.55% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 52 | 25.19 | 106.43% | 8 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 85 51 | 15.13 | 237.08% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 5 5 | 0.97 | 415.46% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 36 36 | 11.77 | 205.86% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 11 11 | 7.54 | 45.89% | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 11 11 | 3.19 | 244.83% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 4 | 3.1 | 29.03% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 37 37 | 9.6 | 285.42% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 13 13 | 5.32 | 144.36% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 13 | 3.06 | 324.84% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 74 74 | 61.1 | 21.11% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 12 12 | 0.99 | 1112.12% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 1.46 | 447.95% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 57 57 | 19.42 | 193.51% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 7 7 | 3.86 | 81.35% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 65 | n/a | n/a | 8 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 3 8 | 1.08 | 640.74% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 0.64 | 1150% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 52 | 12.53 | 315% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 39 35 | 12.72 | 175.16% | 5 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 9 | 1.66 | 442.17% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 1 | n/a | n/a | 4 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 3 | n/a | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 36 | n/a | n/a | 2 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 50 70 | n/a | n/a | 4 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 9 2 | n/a | n/a | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 136 17 | n/a | n/a | 3 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 5 9 | n/a | n/a | 6 | Jun 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 2 4 | 3.48 | 14.94% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1500 250 | n/a | n/a | 1 | Mar 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 3 | n/a | n/a | 3 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 34 | n/a | n/a | 1 | Apr 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 120 160 | n/a | n/a | 1 | Feb 22, 2017 |